The most common gene mutation in Parkinson’s triggers disease outside the brain by changing the body’s immune response to common infections, a study in mice reports. The research, “Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo,” was published in the journal Brain.
An innovative Positron Emission Tomography (PET) tracer that has the potential to diagnose Parkinson’s disease will soon be tested in humans for the first time. Led by Switzerland-based AC Immune, which developed the technology, the study is expected to begin in the second half of 2018. The company recently presented…
Despite being used for the past 30 years to treat chronic neurological diseases, including Parkinson’s disease (PD), deep brain stimulation (DBS) “remains a fascinating puzzle to scientists, physicians, and engineers,” the lead author of a new review study said. Challenges the technique presents for both…
Parkinson’s disease patients treated with Gocovri (amantadine) experienced a 41 percent decrease in levodopa-induced dyskinesia compared to 14 percent of healthy people who took placebos. That analysis of two Phase 3 trials are summarized in the study “Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for…
The Michael J. Fox Foundation (MJFF) announced a new $7 million funding program to support Parkinson’s disease research and accelerate development of new therapeutic targets and biomarkers. Through the program, researchers can request project funding in four major research areas. The organization is now accepting pre-proposals through May 2018,…
A common Parkinson’s gene mutation plays a role in the formation of fatty plaque in the brain that can destroy nerve cells controlling movement, a study suggests. The research, “GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers,” was published in the Proceedings of the National Academy…
Lundbeck will acquire the biopharmaceutical Prexton Therapeutics, obtaining the development and commercialization rights to foliglurax (PTX002331), an investigational therapy currently in Phase 2 trials for Parkinson’s disease. Foliglurax is a small molecule modulator that activates nerve cells with a set of specific glutamate receptors called mGluR4, and compensates…
A comprehensive data set of the human brain was developed by researchers at Emory University in Atlanta as a valuable resource likely to advance knowledge on the mechanisms behind both Parkinson’s (PD) and Alzheimer’s disease (AD). The data was published in a report titled, …
Low levels of two dopamine-related molecules in cerebrospinal fluid can help identify patients in the early stages of preclinical Parkinson’s disease, a study suggests. The study, “Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson’s disease,” was published in Parkinsonism & Related Disorders. Parkinson’s disease is mainly…
GeneFo has created a free state-by-state guide for Parkinson’s patients with detailed and relevant information on medical cannabis, including the application process. Updated to March 2018, the guide may help patients get additional therapy and improve their lives. It includes legal information, patient’s rights, an application checklist, links and forms to…
Get regular updates to your inbox.
